Kuros Biosciences AG (KURN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 841M
Fair value as of: Jun 24, 2026
From 15 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from CHF 1.61 to CHF 2.50 (+55.3%) since Jun 23, 2026. Share price −9.6% over the past month.
Price vs Fair Value (12 months)
12‑month range CHF 16.79 – CHF 31.48 · fair‑value band CHF 1.75 – CHF 3.25 · the CHF 18.21 price screens above the CHF 2.50 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Kuros Biosciences AG (KURN) currently trades at CHF 18.21, while our model-based Fair Value estimate is CHF 2.50 — implying the stock looks roughly 86.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Kuros Biosciences AG generated revenue of CHF 146M at a net margin of 1.8%. Revenue grew 66.9% year over year. It earns a return on equity of 3.3%. The balance sheet holds a net cash position of CHF 11.7M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kuros Biosciences AG reported revenue of CHF 121M in FY2025 versus CHF 13.8M in FY2021, a compound +72.1%/yr. Reported net income was CHF 2.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kuros Biosciences AG (KURN) undervalued?
What is the fair value of KURN?
What is the quality score of KURN?
What is the revenue of Kuros Biosciences AG (KURN)?
What is the net profit margin of KURN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.